在密码性中风中接受前入院抗血小板治疗:双刃剑
Jessica Seetge1, Balázs Cséke2, Zsófia Nozomi Karádi1
1Stroke Unit, Department of Neurology, University of Pécs, 7624 Pécs, Hungary.
Journal of clinical medicine
|February 26, 2025
概括
服用前的抗血小板治疗 (APT) 与密码性中风患者的治疗结果更差有关. 这项研究建议重新考虑APT.
科学领域:
- 神经学 神经学
- 心血管医学 心血管医学
- 临床研究 临床研究
背景情况:
- 密码性中风是一种急性缺血性中风 (AIS) 的亚型,尽管进行了调查,但缺乏明确的原因.
- 服用前抗血小板治疗 (APT) 对密码性中风结果的影响尚未得到充分证实.
- 目前的APT指南主要基于其他中风亚型.
研究的目的:
- 研究入院前抗血小板治疗 (APT) 与密码性中风患者的功能性结局之间的关联.
- 为了确定是否入院前的APT会影响中风后90天的恢复.
主要方法:
- 对224名加密性中风患者的回顾性分析.
- 倾向分数匹配 (PSM) 创建了一个122名患者的平衡队列.
- 后勤回归和调解分析评估了入院前APT和90天的良好结果之间的联系 (修改的兰金度表0-2).
主要成果:
- 在入院前接受APT的患者相比未接受APT (61.7%) 的患者,获得良好结局的比例较低 (39.3%).
- 在PSM和调整混因子 (病发前的mRS,72小时的NIHSS,吸烟) 之后,入院前的APT仍然与较差的结果相关 (aOR=0.21).
- 入院前APT与不利的功能结果之间的关联在统计学上是显著的 (p=0.018).
结论:
- 服用前的抗血小板治疗 (APT) 独立地与密码性中风的功能性结果较差有关.
- 这些发现挑战了APT在这种特定的中风群体中所扮演的保护作用.
- 需要进一步的前性研究来澄清APT在密码性中风管理中的最佳使用.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
455
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
455
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
592
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
592
01:22Formation of the Platelet Plug
3.8K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
3.8K
01:16Clot Retraction and Fibrinolysis
3.4K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.4K